RAPP
HealthcareRapport Therapeutics, Inc. Common Stock · Biotechnology · $1B
What is Rapport Therapeutics, Inc. Common Stock?
Rapport Therapeutics is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing small molecule medicines for central nervous system disorders. The company targets conditions where existing treatments leave significant unmet patient need.
Rapport Therapeutics discovers and develops small molecule drug candidates designed to act on specific receptor subtypes in the brain and nervous system. Its lead program targets a receptor complex implicated in focal epilepsy, neuropathic pain, and bipolar disorder. A second program pursues a differentiated chemical approach to the same receptor family, while additional programs address chronic pain and hearing disorders through nicotinic acetylcholine receptor pathways. The company generates no product revenue at this stage, funding operations through capital raises.
Rapport Therapeutics was incorporated in 2022 and is based in Boston, Massachusetts.
- RAP-219: investigational small molecule for focal epilepsy and CNS disorders
- RAP-199: TARPy8-targeted molecule with differentiated pharmacokinetic properties
- a6 nAChR program targeting chronic pain
- a9a10 nAChR program for hearing disorder treatment
Is RAPP a Good Stock to Buy?
UQS Score rates RAPP as Poor overall, reflecting the early-stage realities of a pre-revenue clinical biotech.
Among the five pillars, Risk stands out as the relative bright spot — a notable distinction for a company at this development stage. This suggests the balance sheet carries enough runway to support near-term pipeline activities without immediate financing distress.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no approved products, no commercial revenue, and a pipeline still in clinical development. Valuation is rated Elevated, meaning the current market price already reflects considerable optimism about unproven outcomes.
See the complete pillar breakdown and underlying financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does RAPP pay dividends?
No — Rapport Therapeutics, Inc. Common Stock does not currently pay a dividend.
Rapport Therapeutics does not pay a dividend, which is typical for clinical-stage biotechs. All available capital is directed toward research, clinical trials, and pipeline advancement. Investors in RAPP are positioned for potential long-term value creation through drug development rather than income distributions.
When does RAPP report earnings?
Rapport Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, quarterly reports focus on cash position, operating expenses, and pipeline milestones rather than sales or profit metrics. Key updates typically center on clinical trial progress and capital runway.
For the most recent quarter's results and pipeline updates, visit Rapport Therapeutics' investor relations page directly.
RAPP Price History
+58.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Rapport Therapeutics, Inc. Common Stock?
Based on Rapport Therapeutics, Inc. Common Stock's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
RAPP Long-term Outlook
The fundamental outlook for RAPP is shaped almost entirely by binary clinical trial outcomes. With Growth and Quality both rated Weak, near-term financial improvement depends on pipeline catalysts rather than organic business expansion. The Good Risk rating provides some reassurance about near-term stability, but the Elevated Valuation pillar signals that the market has priced in a degree of success that remains unproven. Investors should weigh the asymmetric nature of clinical-stage biotech — meaningful upside if trials succeed, significant downside if they do not.
Growth drivers
- Clinical advancement of RAP-219 in focal epilepsy and additional CNS indications
- Differentiated receptor-targeting approach across multiple CNS and pain programs
- Large unmet need in CNS disorders with limited effective existing therapies
Key risks
- Clinical trial failure risk across all pipeline programs
- Elevated valuation leaves little margin of safety if milestones disappoint
- Ongoing capital needs typical of pre-revenue biotechs
RAPP vs Peers
Rapport Therapeutics operates in a competitive clinical-stage landscape alongside other small-cap biotechs pursuing differentiated therapeutic approaches.
Novavax focuses on vaccine development rather than CNS small molecules, representing a different therapeutic modality and commercial stage.
Olema targets oncology indications, distinguishing it from Rapport's exclusive focus on central nervous system and pain disorders.
Wave Life Sciences pursues RNA-based medicines for neurological and other diseases, contrasting with Rapport's small molecule receptor-targeting strategy.
Frequently Asked Questions
What does Rapport Therapeutics do?
Rapport Therapeutics is a clinical-stage biopharmaceutical company developing small molecule medicines for central nervous system disorders. Its pipeline targets focal epilepsy, neuropathic pain, bipolar disorder, chronic pain, and hearing disorders through novel receptor-targeting approaches. The company has no approved products and is currently in the clinical development phase.
Does RAPP pay dividends?
No, Rapport Therapeutics does not pay a dividend. Clinical-stage biotechs at this development phase typically reinvest all available capital into research and clinical trials. Investors seeking income distributions would not find that in RAPP at this stage.
When does RAPP report earnings?
Rapport Therapeutics follows a standard quarterly reporting cadence for US-listed public companies. Because the company is pre-revenue, reports focus on pipeline progress and cash position rather than sales figures. Check the company's investor relations page for the latest scheduled reporting dates.
Is RAPP a good stock to buy?
The UQS Score rates RAPP as Poor overall, driven by Weak readings across Quality, Moat, and Growth pillars. The Risk pillar is the relative standout. Whether RAPP fits a portfolio depends on an investor's risk tolerance for binary clinical outcomes. The full pillar breakdown is available to Pro members on UQS Score.
Is RAPP overvalued?
The UQS Valuation pillar for RAPP is rated Elevated, suggesting the current market price reflects meaningful optimism about pipeline outcomes that have not yet been proven in late-stage trials. This is a common dynamic for clinical-stage biotechs with promising but unvalidated programs.
How does RAPP compare to its competitors?
Rapport Therapeutics occupies a distinct niche within the small-cap biotech space, focused exclusively on CNS small molecules. Peers like Wave Life Sciences pursue RNA-based approaches, while others like Olema focus on oncology. Each carries its own risk and development profile. The UQS Score provides a side-by-side quality comparison for Pro members.
What is RAPP's market cap bracket?
Rapport Therapeutics is classified as a small-cap company. This places it in a segment of the market characterized by higher volatility, greater sensitivity to clinical news, and more limited institutional coverage compared to large- or mega-cap peers.
Who founded Rapport Therapeutics?
Rapport Therapeutics was incorporated in 2022, formerly operating under the name Precision Neuroscience NewCo, Inc. before adopting its current name in October 2022. Founding details and leadership background are publicly available through the company's official disclosures and SEC filings.
Is RAPP a long-term quality investment?
As a long-term quality indicator, the UQS Score rates RAPP as Poor, reflecting the absence of established revenue, competitive moat, or demonstrated business quality at this stage. Long-term value depends almost entirely on clinical success. Pro members can view the full pillar breakdown to assess how RAPP compares within the healthcare sector.
What is the main competitive advantage of Rapport Therapeutics?
Rapport's differentiation lies in its receptor-subtype selectivity approach — designing small molecules that target specific receptor complexes in the nervous system with high precision. If validated clinically, this could offer improved efficacy and tolerability over broader-acting existing treatments. However, this advantage remains unproven at a commercial scale.
What sector does RAPP belong to?
Rapport Therapeutics operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. The company's focus on CNS disorders places it in a subsector known for high scientific complexity, long development timelines, and significant binary risk around trial outcomes.
Is RAPP a growth stock or value stock?
Based on the UQS pillar profile, RAPP carries a Weak Growth rating and an Elevated Valuation rating — a combination that fits neither a traditional growth nor value profile. It is better characterized as a speculative clinical-stage biotech where returns depend on pipeline milestones rather than current financial performance.
Unlock Full RAPP Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access underlying financial metrics driving each pillar
- ✓Compare RAPP against sector peers on quality and risk
- ✓Track pipeline-stage companies across the healthcare sector
- ✓Get the complete analyst-style breakdown in one place
Pro Analysis
RAPP — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 16.0 | 0.0 | 11.0 | 14.0 | 69.9 | 0.0 | +6.3 |
| May 9, 2026 | 9.7 | 0.0 | 11.0 | 0.0 | 46.2 | 0.0 | -3.9 |
| Apr 4, 2026 | 13.6 | 0.0 | 11.0 | 0.0 | 72.1 | 0.0 | 0.0 |
| Apr 2, 2026 | 13.6 | 0.0 | 11.0 | 0.0 | 72.2 | 0.0 | — |
RAPP — Pillar Breakdown
Quality
— 0.0/100 (25%)Rapport Therapeutics, Inc. Common Stock currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 14.0/100 (20%)Rapport Therapeutics, Inc. Common Stock faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 69.9/100 (15%)Rapport Therapeutics, Inc. Common Stock maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Rapport Therapeutics, Inc. Common Stock appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Rapport Therapeutics, Inc. Common Stock operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for RAPP.
Score Composition
Financial Data
More Stock Analysis
How is the RAPP UQS Score Calculated?
The UQS (Unified Quality Score) for Rapport Therapeutics, Inc. Common Stock is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Rapport Therapeutics, Inc. Common Stock's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Rapport Therapeutics, Inc. Common Stock is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.